All-cause mortality and composite or Q-wave myocardial infarction
Time frame · Chart review 6 months after PCI
6-month rates of all-cause mortality and the composite of all-cause mortality or Q-wave myocardial infarction.
Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Status
Withdrawn
Phase
Not applicable
Enrollment
0
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center. It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.
Full detailed description
This is a retrospective, observational, data analysis of approximately 800 patients who underwent primary Percutaneous Coronary Intervention at our institution since September 2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to Percutaneous Coronary Intervention will be excluded. This analysis is estimated to take 1-2 months.
Interventions
Treatment arms and agents.
No intervention details reported.
Timeline
From registration to results.
First posted
Nov 25, 2013
Study start
Oct 2013
Primary completion
Oct 2014
Study completion
Jun 2021
Results posted
Not reported
Registry updated
Jul 2, 2021
Outcomes
What the study measures.
Primary outcomes
Secondary outcomes
TIMI major bleeding
Time frame · During hospital stay; average stay is less than 48 hours
Thrombolysis In Myocardial Infarction (TIMI) major bleeding during hospital stay.
Eligibility
Who can take part.
- Minimum age
- Not reported
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Underwent Percutaneous Coronary Intervention at Washington Hospital Center since September 2000 * Either received eptifibatide pre-or during PCI or have received no eptifibatide. Exclusion Criteria: * Patients who received a thrombolytic prior to Percutaneous Coronary Intervention.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Washington Hospital Center
Washington D.C., District of Columbia, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Eptifibatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
Xinqiao Hospital of Chongqing · Acute Ischemic Stroke
Phase 3
Not yet recruiting
786
2026-01
Multi-arm Optimization of Stroke Thrombolysis
Washington University School of Medicine · Acute Ischemic Stroke
Phase 3
Completed
514
2025-02
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Organon and Co · Myocardial Ischemia · Acute Coronary Syndrome
Phase 3
Completed
9,406
2024-05
Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic
Baylor College of Medicine · Acute Ischemic Stroke
Phase 1 / Phase 2
Unknown
30
2022-06
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Medicure · Myocardial Infarction · Acute Coronary Syndromes
Phase 2
Completed
535
2021-05
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
University of Alabama at Birmingham · Acute Coronary Syndrome · Angina, Unstable
Phase 2
Completed
100
2020-05
Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)
Ministry of Science and Technology of the People´s Republic of China · Acute Ischemic Stroke
Phase 3
Unknown
220
2019-06
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Icahn School of Medicine at Mount Sinai · Stable Angina
Phase 2
Completed
36
2018-02
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.